Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The worldwide increase in obesity and diabetes has led to a spike in non-alcoholic fatty liver disease, which often progresses to the more severe condition non-alcoholic steatohepatitis. This Outlook discusses topics such as the surge in drug development that is poised to deliver new treatments; how innovative technologies are enabling earlier diagnosis; and the disturbing rise of fatty liver disease in children.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
Biotechnology start-ups and pharmaceutical giants alike are charging ahead to develop therapies for the most serious form of non-alcoholic fatty liver disease.